title: [Mechanisms of sorafenib induced NB4 cell apoptosis].
abstract: OBJECTIVE
  To investigate the effects of sorafenib on human acute promyelocytic leukemia cell NB4 and its mechanism.
  
  
  METHODS
  The human acute promyelocytic leukemia cell NB4 was treated with different concentrations (0, 1.5, 3, 6 and 12 µmol/L) of sorafenib, the proliferation inhibitory rate of NB4 cells was assayed by MTT, the apoptosis of NB4 was determined with flow-cytomatry after treatment; after extraction of total protein, the Western blot was performed to determine the expressions of apoptosis-relatived molecules Caspase-3, Caspase-8 and MCL-1. The mRNA expressions of Caspase-3, Caspase-8 and MCL-1 were determined by RT-PCR.
  
  
  RESULTS
  As compared with the control group, the proliferation of NB4 significantly decreased after treatment with different concentrations of sorafenib. The sorafenib significantly induced the apopotosis of NB4 cells in time- and dose-dependent manners. Furthermore, sorafenib treatment resulted in the obvious increase of the Caspase-3 and Caspase-8 protein and mRNA expressions, and down-regulated the MCL-1 protein and mRNA expressions in NB4 cells.
  
  
  CONCLUSIONS
  Sorafenib can inhibit proliferation and induce apopotosis of human acute promyelocytic leukemia cell NB4 through the expression of Caspase-3 and Caspase-8, and down-regulation of the expression of MCL-1.
authors: Department of Hematology, The First Affiliated Hospital, Xi'an Jiaotong University Medicial College, Xi'an 710061, Shaanxi Province, China; Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Yun-Jie
authors: YJ
authors: Zhang
authors: Department of Hematology, The First Affiliated Hospital, Xi'an Jiaotong University Medicial College, Xi'an 710061, Shaanxi Province, China. E-mail 1iuxin59221@medmail.com.cn.
authors: Xin
authors: X
authors: Liu
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Yan-Ping
authors: YP
authors: Song
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Gang-Can
authors: GC
authors: Li
authors: Department of Hematology, The First Affiliated Hospital, Xi'an Jiaotong University Medicial College, Xi'an 710061, Shaanxi Province, China.
authors: Nai-Cen
authors: NC
authors: Zhou
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Hao
authors: H
authors: Wang
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Qi-Xia
authors: QX
authors: Wang
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Jia
authors: J
authors: Xie
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Guang
authors: G
authors: Li
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Jing-Jing
authors: JJ
authors: Ren
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Fei
authors: F
authors: Gao
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Xiao-Bo
authors: XB
authors: Zhang
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Jin-Qian
authors: JQ
authors: Dai
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Lu
authors: L
authors: Wang
authors: Xi'an Institute of Hematology, The Central Hospital of Xi'an, Xi'an 710003, Shaanxi Province, China.
authors: Jiao
authors: J
authors: Mu
mesh_terms: D000970:Antineoplastic Agents; D017209:Apoptosis; D053148:Caspase 3; D053181:Caspase 8; D045744:Cell Line, Tumor; D015536:Down-Regulation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D000077157:Sorafenib; D006377:T-Lymphocytes, Helper-Inducer
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; C505407:CASP3 protein, human; C505530:CASP8 protein, human; D053148:Caspase 3; D053181:Caspase 8